Side effect profile similarities shared between antidepressants and immune-modulators reveal potential novel targets for treating major depressive disorders

Table 3 CMAP expression signature similarities between human cells treated with rapamycin and antidepressants

CMAP Instance^a	Cell	Number of up-regulated probes^b	Number of down-regulated probes^b	Antidepressant with similar expression signature	Antidepressant Type	P-value of expression signature similarity	Enrichment score^c
4431; 4445; 4466	PC3	108	112	clomipramine	non-selective monoamine reuptake inhibitors	0.04844	0.627
1207; 1221; 1242	PC3	84	82	amoxapine	non-selective monoamine reuptake inhibitors	0.01139	0.664
				protriptyline		0.01156	0.724
				maprotiline		0.01993	0.688
987; 1001; 1022	MCF7	27	56	desipramine	non-selective monoamine reuptake inhibitors	0.01156	0.724
				zimeldine	selective serotonin reuptake inhibitors	0.00537	0.704
				fluoxetine	selective serotonin reuptake inhibitors	0.03	0.661
1045; 1059; 1080	MCF7	4	182	clomipramine	non-selective monoamine reuptake inhibitors	0.01017	0.732
				protriptyline		0.00346	0.795
				nortriptyline		0.00109	0.837
5567; 5581; 5602	MCF7	125	67	amoxapine	non-selective monoamine reuptake inhibitors	0.03467	0.593
				trimipramine		0.04345	0.635
				nortriptyline		0.0219	0.682
6967; 6981; 7001	MCF7	44	51	clomipramine	non-selective monoamine reuptake inhibitors	0.0157	0.705
				protriptyline		0.02538	0.672
				nortriptyline		0.0192	0.69
6927; 6940; 6958	MCF7	25	60	amitriptyline	non-selective monoamine reuptake inhibitors	0.01422	0.596

^aThe ID of the instances from CMAP database used to generate the query expression signature for rapamycin
^bNumber of up and down regulated probes of the querying expression signature determined after 1.5 fold change in expression level between drug-treated cells and control cells
^cA measure of the enrichment of the instances for antidepressant in the list of all instances ordered by expression profile similarity score

ISSN: 2050-6511